Last reviewed · How we verify
NCT07515963
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
Phase 2 trial testing FULIRI combination targeted therapy in Colo-rectal Cancer in 24 participants. Not yet recruiting.
1 February 2027
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 June 2026 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 February 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- FULIRI combination targeted therapy
Conditions studied
- Colo-rectal Cancer — all drugs for Colo-rectal Cancer →
Sponsor
Zhongnan Hospital
Who can join
Adults 18 to 75, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as first-line conversion therapy for colorectal cancer with liver metastases. Eligible patients with colorectal cancer and liver metastases, after signing informed consent, received FULIRI chemotherapy combined with bevacizumab/cetuximab targeted therapy. Efficacy was assessed after every four treatment cycles, followed by multidisciplinary team (MDT) discussion regarding potential surgical resection, ablation, or stereotactic radiotherapy. The primary endpoint was the objective response rate (ORR), and secondary endpoints included: disease control rate (DCR), R0 resection rate of liver metastases, progression-free survival (PFS), 3-year/5-year survival rates, and the incidence of acute toxicities of any grade and grades 3/4.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07515963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colo-rectal Cancer
Currently open trials in the same condition.
- NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
- NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
- NCT06880055 — Shield Post-Approval Study Protocol · recruiting
- NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
- NCT07385950 — Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumor · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07515963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07515963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing